Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.

Biotechnology

Mnemo Therapeutics

Robert Lacaze

Ikram H.

Theodoros Giavridis

Michael Saitakis

Nil Ege

Bertrand Vannier

Justin Eyquem

Bénédicte Balland

Christine Foster

Nadia Kaci-Chaouche

Alain Maiore

Mariana Gajardo

The board of directors at Mnemo Therapeutics has a history of experience with universities and cancer centers. Some members have been assistant professors, while others have been principal investigators and postdoctoral research fellows. One member even did an internship at a university. This variety of experience and education provides the board with a well-rounded perspective when it comes to making decisions for the company.

Board of Directors

Leadership Team

Founding Team

Board of Directors

About

Team members

Other teams at Mnemo Therapeutics

Leadership Team

Founding Team